Generic Name and Formulations:
Eszopiclone 1mg, 2mg, 3mg; tabs.
Indications for LUNESTA:
Insomnia (decreased sleep latency and improved sleep maintenance).
Use lowest effective dose. ≥18yrs: Initially 1mg immediately before bedtime [take only if able to get full night's sleep (7–8hrs) before becoming active again]; may increase to 2–3mg if needed; max 3mg/dose. Elderly, debilitated, concomitant CYP3A4 inhibitors (see Interactions), or severe hepatic impairment: max 2mg/dose. Effect delayed if taken with heavy/high-fat meals.
<18yrs: not established.
Monitor for excess CNS depressant effects and impairment. Depression. Abnormal thinking and behavioral changes. Drug or alcohol abuse. Compromised respiratory function. Conditions that affect metabolism or hemodynamic response. Severe hepatic impairment. Avoid abrupt cessation. Reevaluate if unresponsive after 7–10 days of treatment. Write ℞ for smallest practical amount. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers.
Concomitant other sedative-hypnotics at bedtime or middle of the night: not recommended. Potentiates CNS depression with alcohol, other CNS depressants; adjust dose. Potentiated by CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir); reduce eszopiclone dose. May be antagonized by CYP3A4 inducers (eg, rifampicin).
Unpleasant taste, headache, somnolence, dizziness, dry mouth, infection, rash, anxiety, hallucinations, pain; complex sleep-related behaviors (eg, sleep-driving; consider discontinuing if occurs); rare: anaphylaxis, angioedema, others (see full labeling).
Tabs 1mg—30; 2mg, 3mg—100
Endocrinology Advisor Articles
- Use of In-Hospital Continuous Subcutaneous Insulin Infusion: A Consensus Statement
- Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes
- Achieving Glycemic Control in T2D After Basal Insulin Initiation
- Osteoporosis Drug Shows Cardioprotective Potential at 10-Year Follow-Up
- Effects of the Two Types of Anorexia Nervosa on Bone Metabolism
- Diabetes Treatments
- Incretins, Thiazolidinediones Associated With Better Glycemic Control in T2D
- No Link Between HbA1c Levels and Wound Healing in Patients With Diabetic Foot Ulcers
- Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
- Risk for Iodine Deficiency and Hypothyroidism High in Children on Parenteral Nutrition
- Inverse Association Between Serum 25(OH)D Levels and Risk for Diabetes
- Glycemic Control Variations for Children, Adolescents With T1D in High-Income Countries
- Late-Life Mobility Limitations Linked to Obesity After Arthroplasty for OA in Women
- Fracture Risk Should Be Monitored in Bisphosphonate Drug Holiday
- Provider Counseling for Weight Loss Up for Arthritis, Overweight